|
|
 |
|
 |
|
Relief Of Scalp Dermatoses |
|
| Luxíq Provides Scalp-Specific Efficacy |
- 90–100% clearance of moderate to severe scalp psoriasis was achieved in just 28 days in the majority of patients treated with Luxíq (betamethasone valerate) Foam, 0.12%1,2
- Statistically significant reductions compared to betamethasone valerate lotion in plaque thickness and erythema1
- Statistically significant reductions compared to placebo in scaling, plaque thickness, erythema, and pruritus1
|
|
| Safe and Well Tolerated |
- The most frequent side effects associated with the use of Luxíq are mild and transient burning, stinging, or itching at the application site
|
|
- Luxíq is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp, such as psoriasis, eczema, and seborrheic dermatitis.
|
|
References: 1. Luxíq NDA. 2. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-632.
|
|
